Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Rule

Showing results (111-120 of 121) with videos related to

Pageof 13
Sort By:
Leukemia & Lymphoma|April 7, 2000
FLUDAP: salvage chemotherapy for relapsed/refractory aggressive non-Hodgkin's lymphomaJ A Child, S A Johnson, S Rule, et al.
Leukemia|July 19, 2014
The EBMT/EMCL consensus project on the role of autologous and allogeneic stem cell transplantation in mantle cell lymphomaS Robinson, P Dreger, D Caballero, et al.
Msphere|December 17, 2020
Suppressor Mutations in Type II Secretion Mutants of Vibrio cholerae: Inactivation of the VesC ProteaseChelsea S Rule, Young-Jun Park, Jaclyn R Delarosa, et al.
Molecular Microbiology|October 12, 2013
Flow cytometry-based enrichment for cell shape mutants identifies multiple genes that influence Helicobacter pylori morphologyLaura K Sycuro, Chelsea S Rule, Timothy W Petersen, et al.
Blood|November 1, 1995
Bone marrow transplantation for chronic myeloid leukemia with volunteer unrelated donors using ex vivo or in vivo T-cell depletion: major prognostic impact of HLA class I identity between donor and recipientA Spencer, R M Szydlo, P A Brookes, et al.
Bone Marrow Transplantation|January 26, 2006
Fludarabine phosphate and melphalan: a reduced intensity conditioning regimen suitable for allogeneic transplantation that maintains the graft versus malignancy effectR K Dasgupta, S Rule, P Johnson, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 29, 2020
Favourable outcomes for high-risk diffuse large B-cell lymphoma (IPI 3-5) treated with front-line R-CODOX-M/R-IVAC chemotherapy: results of a phase 2 UK NCRI trialA K McMillan, E H Phillips, A A Kirkwood, et al.
Biochemistry|March 22, 2018
Design of Bivalent Nucleic Acid Ligands for Recognition of RNA-Repeated Expansion Associated with Huntington's DiseaseShivaji A Thadke, J Dinithi R Perera, V M Hridya, et al.
Leukemia|March 25, 2018
Ibrutinib versus temsirolimus: 3-year follow-up of patients with previously treated mantle cell lymphoma from the phase 3, international, randomized, open-label RAY studyS Rule, W Jurczak, M Jerkeman, et al.
Leukemia|October 14, 2018
Updated results from the phase 3 HELIOS study of ibrutinib, bendamustine, and rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphomaG Fraser, P Cramer, F Demirkan, et al.
Pageof 13

Showing results (111-120 of 121) with videos related to

Sort By:
Pageof 13
Leukemia & Lymphoma|April 7, 2000
FLUDAP: salvage chemotherapy for relapsed/refractory aggressive non-Hodgkin's lymphomaJ A Child, S A Johnson, S Rule, et al.
Leukemia|July 19, 2014
The EBMT/EMCL consensus project on the role of autologous and allogeneic stem cell transplantation in mantle cell lymphomaS Robinson, P Dreger, D Caballero, et al.
Msphere|December 17, 2020
Suppressor Mutations in Type II Secretion Mutants of Vibrio cholerae: Inactivation of the VesC ProteaseChelsea S Rule, Young-Jun Park, Jaclyn R Delarosa, et al.
Molecular Microbiology|October 12, 2013
Flow cytometry-based enrichment for cell shape mutants identifies multiple genes that influence Helicobacter pylori morphologyLaura K Sycuro, Chelsea S Rule, Timothy W Petersen, et al.
Blood|November 1, 1995
Bone marrow transplantation for chronic myeloid leukemia with volunteer unrelated donors using ex vivo or in vivo T-cell depletion: major prognostic impact of HLA class I identity between donor and recipientA Spencer, R M Szydlo, P A Brookes, et al.
Bone Marrow Transplantation|January 26, 2006
Fludarabine phosphate and melphalan: a reduced intensity conditioning regimen suitable for allogeneic transplantation that maintains the graft versus malignancy effectR K Dasgupta, S Rule, P Johnson, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 29, 2020
Favourable outcomes for high-risk diffuse large B-cell lymphoma (IPI 3-5) treated with front-line R-CODOX-M/R-IVAC chemotherapy: results of a phase 2 UK NCRI trialA K McMillan, E H Phillips, A A Kirkwood, et al.
Biochemistry|March 22, 2018
Design of Bivalent Nucleic Acid Ligands for Recognition of RNA-Repeated Expansion Associated with Huntington's DiseaseShivaji A Thadke, J Dinithi R Perera, V M Hridya, et al.
Leukemia|March 25, 2018
Ibrutinib versus temsirolimus: 3-year follow-up of patients with previously treated mantle cell lymphoma from the phase 3, international, randomized, open-label RAY studyS Rule, W Jurczak, M Jerkeman, et al.
Leukemia|October 14, 2018
Updated results from the phase 3 HELIOS study of ibrutinib, bendamustine, and rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphomaG Fraser, P Cramer, F Demirkan, et al.
Pageof 13